Takeda to hold the commencement ceremony for Construction ofNew Research Facilities
OSAKA, Japan, July 3, 2009 --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced that it held the commencement ceremony of new research facilities, which straddle the border of the cities of Fujisawa and Kamakura in Kanagawa Prefecture, Japan. Takeda anticipates completion of the research facilities before the end of fiscal 2010.
Takeda looks forward to continuing its open dialogue with and asks for the continuing cooperation and support of the prefectural and municipal authorities, local residents, and other stakeholders. The Company is taking all possible steps for rigorous preservation of the environment and for assurance of safety during the construction.
The new research facilities will serve as the center of Takeda's global research network. Through the establishment of this world-class facility and its outstanding drug discovery capabilities, Takeda will further increase its dynamism and global appeal to researchers of all levels. Takeda aims to realize its stated mission of "striving toward better health of individuals and progress of medicine by developing superior pharmaceutical products," as well as its aspiration of being a company that grows together with its shareholders and all other stakeholders.
# # #
News Source : Takeda to hold the commencement ceremony for Construction ofNew Research Facilities
More User Press Releases
- Notice Concerning Stock Options (Stock Acquisition Rights) for Members of the Board of Directors, Corporate Officers and Senior
- Takeda Announces Appointment of New Directors Including New Assignment, Corporate Officers, Management of Takeda Pharmaceuticals
- Takeda to Start Internship Program for Tsinghua University of China
- Hib Vaccine TAK-816 Enters into the Phase III Clinical Trial in Japan
- Takeda filed ACTOSPatent Litigations against Generic Companies in Japan
- DATA PRESENTATIONS SHOWCASE MILLENNIUM LEADERSHIP IN PROTEIN HOMEOSTASIS AT 16CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION
- Millennium and Seattle Genetics Present Clinical Data on ADCETRIS(Brentuximab Vedotin) in Systemic ALCL at EHA Annual Meeting
- Millennium and Seattle Genetics Present Clinical Data on ADCETRIS(Brentuximab Vedotin) in Hodgkin Lymphoma at EHA Annual Meeting
- Actions Taken on Actosand Competactby French Regulatory Authorities
- Millennium Highlights New Protein Homeostasis Data in Metastatic Melanoma and Other Solid Tumors at American Society of Clinical
Bookmark/Search this post
Bookmark/Search this post
Primary Menu
- Business
- List of Industries
- Technology
- Aerospace & Defense
- Agriculture & Forestry
- Arts
- Automotive
- Business Services
- Chemicals
- Construction & Maintenance
- Consumer Goods
- Education
- Electrical & Electronics
- Energy
- Entertainment
- Food & Related Products
- General Business
- Government
- Healthcare
- Heavy Industry
- Home
- Industrial Goods & Services
- Industrial Materials
- Medical
- Mining & Drilling
- Publishing & Printing
- Retail
- Society
- Sports
- Supermarkets
- Telecommunications
- Textiles & Nonwovens
- Transportation & Logistics
- Travel & Hospitality
- Wholesale
- News by Region













